Clinical-stage drug development company Woolsey Pharmaceuticals Inc reported on Wednesday that its BRAVYL (fasudil) has demonstrated positive results in a Phase 2a Amyotrophic Lateral Sclerosis (ALS) study.
BRAVYL significantly reduced Neurofilament Light (NfL), a marker of nerve cell damage, and showed trends towards improved clinical outcomes.
NfL levels decreased by 15% from baseline to 6 months. Since NfL in the ALS population tends to increase by a mean of 11% in 6 months, this suggests that 180 mg/day BRAVYL could potentially reduce NfL up to 26% versus placebo over 6 months.
Additionally, greater decreases in NfL were correlated with less decline in ALS functional scores, suggesting potential clinical benefits.
A separate analysis compared trial data with matched ALS patients. REAL patients showed slower decline in breathing capacity, muscle strength and ALS function compared to controls.
The trial is ongoing with a higher dose being evaluated for safety and efficacy.
Inify Laboratories expands to UK, enters gastrointestinal diagnostics
Eli Lilly's Kisunla gains UK marketing authorisation for alzheimer's treatment
TC BioPharm agrees research planning collaboration to develop Monkeypox treatment
Grifols partners with BARDA to develop treatment for sulfur mustard eye injury
Swedish AI Medical Technologies to begin trial for AI melanoma diagnostic tool
Adcentrx Therapeutics' ADRX-0405 IND application approved by US FDA
HELP Therapeutics' HiCM-188 IND application receives US FDA approval
Trevi Therapeutics finishes enrollment in RCC Phase 2a trial
REGENXBIO reveals positive data for ABBV-RGX-314 in bilateral wet AMD